Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Rectal Cancer treatment details. Biologic therapy. Chemotherapy. Royal Marsden Hospital, Surrey, United Kingdom

Survival: 14.7 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Adrucil
Country: United Kingdom
City/State/Province: Surrey
Hospital: Royal Marsden Hospital
Journal: Link
Date: 11/2005

Patients: This Phase III study involved 630 patients with previously untreated metastatic colorectal cancer. The patients were randomized into two groups. Group A had 422 patients (257 men, 165 women) with a median age of 64 years. Of the 422 patients, 311 had colon cancer and 111 had rectal cancer.

Treatment: The treatment consisted of two chemotherapeutic agents: fluorouracil and leucovorin. In addition, Group A received a biological therapy agent 3H1, a monoclonal antibody against the carcinoembryonic antigen (CEA).

Toxicity: For Group A, grade 3-4 toxicities included neutropenia, diarrhea, abdominal pain, dehydration, and stomatitis.

Results: The median overall survival was 14.7 months for Group A and 15.2 months for Group B. The authors observed that while,"3H1 is safe and effectively induces immune responses to CEA [the] addition of 3H1 to 5-FU and LV was not shown to improve overall patient outcomes."

Support: Several of the authors were employees of Titan Pharmaceuticals. Titan Pharmaceuticals develops and manufactures the 3H1 monoclonal antibody used in this study.

Correspondence: Dr. D. Cunningham

E-mail to a Friend Email Physician More Information